Summary
Excerpt |
---|
This collection contains data from the National Cancer InstituteSouthwest Oncology Group (SWOG) Clinical Trial NCT00946712, "“Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer". Principle Investigator: Roy Herbst. It was sponsored by NCI 's Alliance for Clinical Trials in Oncologyand performed by the Southwest Oncology Group under study number S0819. This randomized phase III trial studies carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or non-small cell lung cancer that has returned after a period of improvement (recurrent). Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may prevent the growth of new blood vessels that tumor needs to grow. Cetuximab may also stop cancer cells from growing by binding and interfering with a protein on the surface of the tumor cell that is needed for tumor growth. It is not yet known whether giving Carboplatincarboplatin and Paclitaxelpaclitaxel are more effective with or without Bevacizumabbevacizumab and/or Cetuximabcetuximab in treating patients with non-small cell lung cancer. Select patient-level data from this trial is available via the following link: https://nctn-data-archive.nci.nih.gov/node/850. Trial OutcomesResults of the trial have been reported in the following publications:
|
Acknowledgements
We would like to acknowledge the individuals and institutions that have provided data for this collection:
...
Localtab Group | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
...